Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions
28. Januar 2025 09:00 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
14. Januar 2025 08:30 ET
|
Intelligent Bio Solutions, Inc.
Princebuild has moved from saliva testing to INBS' fingerprint drug testing solution to implement a more streamlined, in-house solution across seven sites.
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
18. Dezember 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions to Host Virtual Fireside Chat on Wednesday, December 11th at 4:30 p.m. ET
04. Dezember 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
26. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of...
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
21. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
13. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
07. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
31. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
29. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary...